New! Search for patents from more than 100 countries including Australia, Brazil, Sweden and more

WO2010071313A3 - 라시디핀 함유 과립 및 이를 포함하는 약학 조성물 - Google Patents

라시디핀 함유 과립 및 이를 포함하는 약학 조성물 Download PDF

Info

Publication number
WO2010071313A3
WO2010071313A3 PCT/KR2009/007212 KR2009007212W WO2010071313A3 WO 2010071313 A3 WO2010071313 A3 WO 2010071313A3 KR 2009007212 W KR2009007212 W KR 2009007212W WO 2010071313 A3 WO2010071313 A3 WO 2010071313A3
Authority
WO
WIPO (PCT)
Prior art keywords
lacidipine
present invention
pharmaceutical compositions
same
containing
Prior art date
Application number
PCT/KR2009/007212
Other languages
English (en)
French (fr)
Other versions
WO2010071313A2 (ko
Inventor
박영준
정은경
Original Assignee
삼일제약주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR10-2008-0127780 priority Critical
Priority to KR1020080127780A priority patent/KR20100069170A/ko
Application filed by 삼일제약주식회사 filed Critical 삼일제약주식회사
Publication of WO2010071313A2 publication Critical patent/WO2010071313A2/ko
Publication of WO2010071313A3 publication Critical patent/WO2010071313A3/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Abstract

본 발명은 라시디핀; 계면활성제; 및 폴리비닐피롤리돈의 혼합물이 수용성 당류의 입자 표면에 코팅되어 형성된, 라시디핀 함유 과립 및 이를 포함하는 약학 조성물에 관한 것이다. 본 발명에 따른 라시디핀 함유 과립은 수성 매질에서 우수한 용출속도 및 용해도를 나타내며, 따라서 높은 생체 이용율을 나타낼 수 있다. 특히, 본 발명에 따른 라시디핀 함유 과립으로부터 얻어진 정제 등의 고형 제제는 종래의 제제에 비하여 30 분까지의 누적 용출율을 약 2 배 이상으로 높일 수 있으므로, 신속한 약리 활성을 나타낼 뿐만 아니라 우수한 생체이용율을 나타낼 수 있다.
PCT/KR2009/007212 2008-12-16 2009-12-04 라시디핀 함유 과립 및 이를 포함하는 약학 조성물 WO2010071313A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR10-2008-0127780 2008-12-16
KR1020080127780A KR20100069170A (ko) 2008-12-16 2008-12-16 라시디핀 함유 과립 및 이를 포함하는 약학 조성물

Publications (2)

Publication Number Publication Date
WO2010071313A2 WO2010071313A2 (ko) 2010-06-24
WO2010071313A3 true WO2010071313A3 (ko) 2010-10-07

Family

ID=42269207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/007212 WO2010071313A2 (ko) 2008-12-16 2009-12-04 라시디핀 함유 과립 및 이를 포함하는 약학 조성물

Country Status (2)

Country Link
KR (1) KR20100069170A (ko)
WO (1) WO2010071313A2 (ko)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439687A (en) * 1992-02-17 1995-08-08 Siegfried Pharma Ag Dosage forms having zero-order dihydropyridine calcium antagonist release
US20080063711A1 (en) * 2006-08-30 2008-03-13 Jagotec Ag Controlled Release Nisoldipine Compositions
US20080241240A1 (en) * 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439687A (en) * 1992-02-17 1995-08-08 Siegfried Pharma Ag Dosage forms having zero-order dihydropyridine calcium antagonist release
US20080241240A1 (en) * 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US20080063711A1 (en) * 2006-08-30 2008-03-13 Jagotec Ag Controlled Release Nisoldipine Compositions

Also Published As

Publication number Publication date
KR20100069170A (ko) 2010-06-24
WO2010071313A2 (ko) 2010-06-24

Similar Documents

Publication Publication Date Title
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
NZ592113A (en) Highly concentrated drug particles, formulations, suspensions and uses thereof
WO2007085833A3 (en) Pyrimidine derivatives
WO2008084698A1 (ja) タクロリムス徐放性医薬組成物
WO2009028598A1 (ja) 徐放性製剤及びその製造方法
WO2006021454A3 (en) Pyrimidine derivatives
WO2007149520A3 (en) Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
WO2008143240A1 (ja) 特定の有機酸を含有する経口製剤並びに経口製剤の溶出性及び化学的安定性の改善方法
WO2006005910A3 (en) Pharmaceutical composition comprising botulinum, a non ionic surfactant, sodium chloride and sucrose
WO2009041651A1 (ja) 速崩壊性固形製剤
WO2007150030A3 (en) Microfluidic synthesis of organic nanoparticles
WO2008147169A3 (es) Microemolsion conteniendo pirfenidona
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
WO2007086001A3 (en) Novel pyridine derivatives
WO2004073703B1 (en) Glycinamide derivative for inhibiting hiv replication
WO2006030323A3 (en) Compounds that inhibit replication of human immunodeficiency virus
WO2005055976A3 (de) Pulver enthaltend niedermolekulares dextran und verfahren zu deren herstellung
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
RU2337687C2 (ru) Фармацевтическая композиция с контролируемым высвобождением и способ ее получения
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
WO2006138735A3 (en) Gel compositions for topical administration
WO2008149788A1 (ja) 固形透析用剤
WO2007089768A3 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
TWI374035B (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09833591

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 09833591

Country of ref document: EP

Kind code of ref document: A2